2023 Was a tough calendar year to the biopharma business, with various providers downsizing and restructuring their workforces to stay afloat. There are signs of recovery, as mergers and acquisitions picked up over the pharmaceutical and existence sciences industry from the latter Portion of 2023 and also have continued their https://sites.google.com/view/bio-sites/blog